A phase i study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 818-823

  Heath, E I ^a   Chiorean, E G ^b   Sweeney, C J ^b   Hodge, J P ^c   Lager, J J ^c   Forman, K ^a   Malburg, L ^a   Arumugham, T ^c   Dar, M M ^c   Suttle, A B ^c   Gainer, S D ^c   Lorusso, P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; GSK 1071306; GSK 1268992; GSK 1268997; GW 00201; GW 700201; PAZOPANIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANOREXIA; ANUS CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG HALF LIFE; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY CANCER; LIPID DIET; LIVER CANCER; LOW FAT DIET; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NAUSEA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SIDE EFFECT; SOLID TUMOR; TESTIS CANCER; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS CANCER; VULVA CANCER;

ADMINISTRATION, ORAL; ADULT; AGED; COHORT STUDIES; CROSS-OVER STUDIES; DIETARY FATS; FATIGUE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; PYRIMIDINES; SULFONAMIDES;

EID: 78449297407     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.199     Document Type: Article

References (17)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
2. Berse, B., Brown, L.F., Van de Water, L., dvorak, H.F. & Senger, d.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed diferentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 3, 211-220 (1992).
3. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002).
4. Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1-18 (2006).
5. Kumar, R. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012-2021 (2007).
6. Sonpavde, G., Hutson, T.E. & Sternberg, C.N. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs 17, 253-261 (2008).
7. Hutson, T.E. et al. efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 28, 475-480 (2010).
8. Altorki, N. et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NScLc): a proof-of-concept study. Ann. Oncol. 19, viii89 (2008).
9. Friedlander, M. et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study. Ann. Oncol. 19, viii211 (2008).
10. Hurwitz, H.I. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227 (2009).
11. Slamon, D.J. et al. Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with frst-line HER2 positive advanced or metastatic (adv/met) breast cancer. Cancer Res. 69, abstr 4114 (2009).
12. Sleijfer, S. et al. Pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a phase II study from the EORTc STBSG (EORTc 62043). Ann. Oncol. 19, viii267 (2008).
13. US Food and drug Administration. Pazopanib [approval notice] (2009). Accessed december 2009.
14. Dressman, J.B. comparison of canine and human gastrointestinal physiology. Pharm. Res. 3, 123-131 (1986).
15. Gressett, S.M. & Shah, S.R. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother. 43, 490-501 (2009).
16. US department of Health and Human Services Food and drug Administration center for drug Evaluation and Research (cdER). Guidance for Industry: Food-effect Bioavailability and Fed Bioequivalence Studies (2002).
17. National cancer Institute. common Terminology criteria for Adverse Events v3.0 (cTcAE) (2006).